Caris Life Sciences Announces a Strategic Collaboration with Ontada® to Advance Oncology Research and the Adoption of Precision Medicine
Txylo.com/10298175
Trending...
- Jason's Deli Unveils Bold New Brand Identity and Restaurant Prototype, Marking the Brand's Next Iteration
- How Technology is Making the Florida Court System More Accessible
- The Power Of Online Reviews & Why They Matter
IRVING, Texas, Jan. 16, 2025 ~ In a groundbreaking move, Caris Life Sciences® (Caris) has announced a strategic collaboration with Ontada®, a leading business in oncology real-world evidence and clinical education. This partnership aims to advance molecular research and cancer care, as well as improve the healthcare delivery system through the use of precision medicine.
According to Caris President David Spetzler, MS, PhD, MBA, this collaboration is rooted in a commitment to rigorous science and cancer care. The partnership will focus on three key pillars: the development and delivery of multimodal data solutions, innovative research strategies, and data-driven practices to provide actionable cancer care intelligence.
The goal of this collaboration is to revolutionize cancer research by seamlessly integrating key entities such as research, biopharma, and patients. By doing so, they hope to drive innovation and ultimately improve patient outcomes.
Ontada President Christine Davis also expressed excitement about the collaboration, stating that by bringing together two extensive clinical and genomic data sets from community oncology settings, they have created a unique resource for life sciences companies. This resource will empower them to address complex questions and potentially lead to groundbreaking research that can improve cancer care.
More on Txylo.com
The collaboration will leverage Caris' molecular-rich database generated from over 6.5 million tests producing over 13 quadrillion datapoints. Additionally, Ontada's industry-leading real-world oncology data representing over 2.4 million cancer patient records across more than 80 tumor types will be available for research. This data is largely derived from community settings where an estimated 85% of cancer patients are treated according to the National Cancer Institute.
By bringing together expertise in cancer care, diagnostics, and drug development, this collaboration goes beyond just providing a combined data solution. It also aims to advance oncology treatment through joint research projects.
Chairman of the Caris Precision Oncology Alliance™ James Hamrick MD MPH believes that this partnership will bridge the gap between research and real-world application. This will create a streamlined pathway from research and development to clinical practice, ultimately benefiting patients with faster access to more informed treatment decisions, personalized therapies, clinical trials, and improved outcomes.
In conclusion, this collaboration between Caris and Ontada marks a transformative approach to cancer care. It fosters innovation, efficiency, and patient-centered outcomes in oncology. With the rapid evolution of oncology, this partnership is poised to deliver insights more quickly and conduct more robust research that will advance precision care.
According to Caris President David Spetzler, MS, PhD, MBA, this collaboration is rooted in a commitment to rigorous science and cancer care. The partnership will focus on three key pillars: the development and delivery of multimodal data solutions, innovative research strategies, and data-driven practices to provide actionable cancer care intelligence.
The goal of this collaboration is to revolutionize cancer research by seamlessly integrating key entities such as research, biopharma, and patients. By doing so, they hope to drive innovation and ultimately improve patient outcomes.
Ontada President Christine Davis also expressed excitement about the collaboration, stating that by bringing together two extensive clinical and genomic data sets from community oncology settings, they have created a unique resource for life sciences companies. This resource will empower them to address complex questions and potentially lead to groundbreaking research that can improve cancer care.
More on Txylo.com
- The Dallas Group of America, Inc. Celebrates the 50th Anniversary of Landmark Facility
- Flywheelr Redefines Executive Thought Leadership as the New Face of B2B Marketing
- Varsity Brands Strengthens Leadership Team with Two Key Executive Appointments
- Texas: Governor Abbott Spotlights Rural Support For School Choice In Athens
- Kelvin Emtech and Colm Engineering Unveil Strategic Joint Venture, to Boost Data Center and Building M&E Capabilities
The collaboration will leverage Caris' molecular-rich database generated from over 6.5 million tests producing over 13 quadrillion datapoints. Additionally, Ontada's industry-leading real-world oncology data representing over 2.4 million cancer patient records across more than 80 tumor types will be available for research. This data is largely derived from community settings where an estimated 85% of cancer patients are treated according to the National Cancer Institute.
By bringing together expertise in cancer care, diagnostics, and drug development, this collaboration goes beyond just providing a combined data solution. It also aims to advance oncology treatment through joint research projects.
Chairman of the Caris Precision Oncology Alliance™ James Hamrick MD MPH believes that this partnership will bridge the gap between research and real-world application. This will create a streamlined pathway from research and development to clinical practice, ultimately benefiting patients with faster access to more informed treatment decisions, personalized therapies, clinical trials, and improved outcomes.
In conclusion, this collaboration between Caris and Ontada marks a transformative approach to cancer care. It fosters innovation, efficiency, and patient-centered outcomes in oncology. With the rapid evolution of oncology, this partnership is poised to deliver insights more quickly and conduct more robust research that will advance precision care.
Filed Under: Business
0 Comments
Latest on Txylo.com
- Citizens for West Virginia Election Integrity Calls for Urgent Reforms to Safeguard State Elections
- City of Sanger Recognizes Shani Bradshaw for Leadership in Bringing Tom Thumb Grocery Store
- Governor Abbott Reappoints McCleskey As Independent Ombudsman For The Texas Juvenile Justice Department
- "FUSE: Premier Office Spaces with Hospitality-Driven Flexibility for Startups & Enterprises"
- Patton Launches SFP-based RS-232/422/485 Serial Device Server
- Texas: Governor Abbott Reappoints Three To Real Estate Research Advisory Committee
- Local Tech Entrepreneur Partners with WonderSouq To Offer Downtown Medford Businesses a Virtual City Experience
- The Continental, powered by Placemakr Set to Launch in San Antonio
- Texas: Governor Abbott Announces Over $138,000 Job Training Grant To Victoria College
- Boston Bridal Atelier Enhances Luxury Experience with New Bridal Shop Location
- New Website for Solo Agers Over 50
- Malcolm-Jamal Warner Returns to Columbia for an Unforgettable Evening of Poetry & Music
- Slightly Stoopid, Damian & Stephen Marley to headline Everwild Music Festival in 2025
- GRAND CANYONS OF THE MOON
- Parkbench13 Media Group Inc. Seeks Artists for Sync Licensing Opportunities
- The Elevated Table Project Revolutionizes Cannabis-Infused Cooking & Cocktails
- South By Southwest Launches SXSW Books Imprint in Partnership with Advantage Media
- Sano Chemicals Inc. (DBA "Sano Women's Health") Announces Approval to Start Phase 1 MAD Study
- Private AI Leader webAI Announces Deal with ŌURA to Power Personalized, On-Device AI
- Curtana Pharmaceuticals Announces Breakthrough in Pediatric Brain Cancer Treatment with Dual Studies Published in Nature Communications